Thumbnail

DIABETIC NEPHROPATHY MARKET - PIPELINE INTELLIGENCE, 2020

Looking to buy the report?

Introduction

Diabetic nephropathy is defined by the presence of proteinuria, and it is a form of chronic kidney disease that occurs when the kidney is exposed to persistent hyperglycemia. It affects approximately 20-40% of patients with diabetes mellitus. The risk of diabetic nephropathy is evenly equivalent in both the type-1 and type-2 diabetes cases.

According to the CDC, diabetes is the most common cause of end stage renal disease (ESRD). In 2011, approximately 26 million of people in the United States were reported to have diabetes, and more than 200,000 people with end stage renal disease due to diabetes, were either on chronic renal dialysis or had a kidney transplant. Diabetic nephropathy is one of the common conditions among the diabetic individuals. All these factors are contributing to the impact of diabetic nephropathy across the globe.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.

Diabetic Nephropathy Clinical Trial Analysis by Phase and Status

  • The clinical trial analysis for diabetic nephropathy indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Diabetic Nephropathy Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information regarding registered clinical trials in different countries, across several developed and emerging markets
  • The major driving factor for the market is the rising number of diabetic cases across the globe. According to the International Journal of Advances in Medicine, by 2030, approximately 79.4 million will have diabetes. And by the time the patient is diagnosed, he/she may have already been affected with some sort of complications, like diabetic nephropathy, and neuropathy

Key Sponsors in Diabetic Nephropathy Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

  • The number of clinical trials that are being conducted worldwide
  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Insights on regional- and country-level data
  • Dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Others

8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy